HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

NCT07647432 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Plasmablastic Lymphoma
HIV
Consolidation

Interventions

DRUG: Elranatamab (Elra)

Sponsor

University of Illinois at Chicago

Collaborators

[object Object]